Albireo Pharma Inc Stock News

- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -

- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -

Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) DarioHealth Corp (NASDAQ:...

‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (N

Dupont Capital Management Corp purchased a new stake in Albireo Pharma Inc (NASDAQ:ALBO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund pur

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — — Enrolled first biliary atresia patients in second odevixibat pivotal study — — Completed two financing transac

Albireo Pharma Inc (NASDAQ:ALBO) saw unusually large options trading on Monday. Traders purchased 2,232 call options on the stock. This represents an increase of 1,154% compared to the typical daily v

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron

— Conference call and webcast to be held at 10:00 a.m. ET —  BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease compa

Given the widespread market volatility, some investors are seeking refuge in more defensible stocks. However, this certainly doesn’t apply to every Wall Street observer. A select group remains ready

Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from...